Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4791125
Max Phase: Preclinical
Molecular Formula: C84H110N28O20
Molecular Weight: 1831.98
Molecule Type: Unknown
Associated Items:
ID: ALA4791125
Max Phase: Preclinical
Molecular Formula: C84H110N28O20
Molecular Weight: 1831.98
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O[C@@H]1[C@H](O)CN[C@H]1Cn1cc(-c2ccc(OCCOCCn3cc(COCC(COCc4cn(CCOCCOc5ccc(-c6cn(C[C@@H]7NC[C@@H](O)[C@H]7O)nn6)cc5)nn4)(COCc4cn(COCCOc5ccc(-c6cn(C[C@@H]7NC[C@@H](O)[C@H]7O)nn6)cc5)nn4)COCc4cnnn4CCOCCOc4ccc(-c5cn(C[C@@H]6NC[C@@H](O)[C@H]6O)nn5)cc4)nn3)cc2)nn1
Standard InChI: InChI=1S/C84H110N28O20/c113-76-32-85-72(80(76)117)43-107-39-68(93-101-107)56-1-9-64(10-2-56)129-27-23-121-20-17-105-36-60(90-98-105)47-125-51-84(53-127-49-62-38-111(100-92-62)55-124-26-30-132-67-15-7-59(8-16-67)71-42-110(104-96-71)46-75-83(120)79(116)35-88-75,52-126-48-61-37-106(99-91-61)18-21-122-24-28-130-65-11-3-57(4-12-65)69-40-108(102-94-69)44-73-81(118)77(114)33-86-73)54-128-50-63-31-89-97-112(63)19-22-123-25-29-131-66-13-5-58(6-14-66)70-41-109(103-95-70)45-74-82(119)78(115)34-87-74/h1-16,31,36-42,72-83,85-88,113-120H,17-30,32-35,43-55H2/t72-,73-,74-,75-,76+,77+,78+,79+,80-,81-,82-,83-/m0/s1
Standard InChI Key: LNNPBCPMIVSJCP-RAVVQHNTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1831.98 | Molecular Weight (Monoisotopic): 1830.8451 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Martínez-Bailén M,Carmona AT,Cardona F,Matassini C,Goti A,Kubo M,Kato A,Robina I,Moreno-Vargas AJ. (2020) Synthesis of multimeric pyrrolidine iminosugar inhibitors of human β-glucocerebrosidase and α-galactosidase A: First example of a multivalent enzyme activity enhancer for Fabry disease., 192 [PMID:32146376] [10.1016/j.ejmech.2020.112173] |
Source(1):